NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
11/08/2026
Voltar para busca
Dado oficial do USPTO
S-CELTENSIFY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
11/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
40, 42
Data de depósito
16/10/2024
Data de registro
11/11/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/11/2025
Última transação
11/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
KR
Examinador
CROSS, TRACY L
Localização atual
Historical data usage
Descrição da marca
The mark consists of the stylized wording "S-Celtensify".
Titulares e representantes
Titulares
Samsung Biologics Co., Ltd.
Representantes
Brian P. Gregg McNees Wallace & Nurick
Classificação técnica
Classes Nice
Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 40
Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylated drugs; processing of chemicals.
Classe 42
Scientific laboratory services for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; scientific research in the field of molecular analysis; development of biotechnology; biotechnological research; scientific research in the field of biological analysis; biological research; scientific research in the field of biologics; scientific research in the field of biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; testing services for assessing the efficiency of pharmaceuticals; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics; computer programming in the medical field; medical research laboratories; * technical support for * computer * software in the field of * project management * of * services relating to imaging medical * imaging * data; medicine research; analysis and evaluation of medical product development; providing information on the testinginspection and research of medical products; providing medical and scientific research information in the field of clinical trial progress; scientific research in the nature of conducting clinical trials for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
06/08/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/07/2026
FIMP
FINAL DISPOSITION PROCESSED
22/07/2026
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
22/07/2026
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
21/07/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
21/07/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
28/05/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/05/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
11/05/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/02/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/11/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
11/11/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
31/10/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/09/2025
PUBO
PUBLISHED FOR OPPOSITION
23/09/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/09/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
23/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/08/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/08/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
18/08/2025
RFNT
REFUSAL PROCESSED BY IB
09/05/2025
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/04/2025
RFRR
REFUSAL PROCESSED BY MPU
18/04/2025
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/03/2025
CNRT
NON-FINAL ACTION WRITTEN
11/03/2025
DOCK
ASSIGNED TO EXAMINER
07/03/2025
MAFR
APPLICATION FILING RECEIPT MAILED
13/12/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/12/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/12/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace S-CELTENSIFY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.